724 organization(s) found
CACA (China Anti-Cancer Association)
The Chinese Anti-Cancer Association (CACA), founded in 1984, has a mission to unite people involved in all branches of oncology and others with a similar interest in fighting cancer. CACA aims its utmost efforts at organizing scientific cooperation and conferences, promoting international non-governmental exchanges, conducting various training courses and seminars, fostering scientific, technological and medical personnel in the field of oncology, compiling and publishing academic periodicals, and mobilizing social forces to take part in popularization and dissemination of the knowledge of tumor prevention. Globally, the association is interested in organizing academic meetings with international colleagues in order to cultivate friendly ties with overseas oncology organizations and individuals. The Chinese Anti-Cancer Association has been a full UICC member since January 1997.
Callio Therapeutics
We are developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies. This enables targeted delivery of drug combinations to tumor cells to maximize therapeutic benefit for cancer patients. Our lead program is a dual-payload HER2-targeted ADC.
Cancer Hospital (Third Affiliated Hospital) of Xinjiang Medical University
Regional cancer hospital in northwest China; participates in national networks for clinical trials and cancer care. (CareAcross)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS Cancer Hospital, Beijing)
National-level top oncology hospital and research centre; historically designated a WHO Collaborating Centre for cancer research and control. It has played key roles in cancer epidemiology, control programmes, training, and research in China. (Iris)
Cancéropôle Est
In French: "Plus de 200 équipes sont mobilisées dans un seul but : développer une recherche compétitive et innovante dans le domaine de la lutte contre le cancer. Au total, 1000 chercheurs et cliniciens unissent leurs efforts afin de faire bénéficier les 8,4 millions d’habitants de l’interrégion Est des avancées en termes de prévention, dépistage, diagnostic et thérapeutique."
Cancéropôle Grand-Ouest
In French: "Le Cancéropôle Grand-Ouest stimule la recherche translationnelle en favorisant la collaboration entre les laboratoires de recherche fondamentale et les unités cliniques, générant ainsi des projets pluridisciplinaires et ambitieux pour permettre aux patients de bénéficier plus rapidement des traitements innovants, tout en contribuant à la structuration et l'attractivité de l'inter-région GO au niveau national et international."
Cancéropôle Île-de-France
Dans le cadre de sa mission d’animation du réseau francilien de recherche en cancérologie, le Cancéropôle Île-de-France propose et relaye toute l’année les annonces de séminaires scientifiques, appels à projets, formations et autres actualités susceptibles d’intéresser les cliniciens et chercheurs franciliens travaillant dans le domaine du cancer, ainsi que les patients et représentants de patients, ou les représentants institutionnels et administratifs.
Cancéropôle Nord-Ouest
In French: "Le Cancéropôle Nord-Ouest (CNO) est une initiative lancée et financée dans le cadre des Plans Cancers nationaux pour soutenir la recherche sur le cancer à l’échelle interrégionale. Relais de terrain, connaissant bien son territoire et ses partenaires institutionnels, il mobilise contre le cancer à l’échelle des Hauts-de-France et de la Normandie. La structure dispose d’un excellent potentiel de recherche, tant au niveau fondamental que translationnel et clinique collaborant autour du thème fédérateur « Du dépistage des tumeurs à l’innovation thérapeutique »."
Canceropôle PACA
In French: "Groupement d’intérêt public, le Canceropôle réunit et sert la communauté académique, scientifique, médicale et industrielle de Provence-Alpes-Côte d’Azur. Depuis 2003, nous agissons au cœur d’un écosystème d’excellence, pour concrétiser la politique nationale de lutte contre les cancers dans une stratégie régionale au bénéfice des patients. Notre mission : propulser les recherches et innovations anticancers, des découvertes fondamentales aux applications thérapeutiques. À l’écoute des besoins, nous animons, soutenons, accompagnons les chercheurs et les équipes dans différentes disciplines pour accélérer l’avancée vers les thérapies de demain. Nous favorisons la maturation et le transfert des résultats de recherche vers la médecine et l’industrie, pour développer plus vite de nouveaux outils, diagnostics et traitements."
CANSA (Cancer Association of South Africa)
Non-profit leader in the fight against cancer; enables research, education, public awareness, support and advocacy for all cancer patients in South Africa.
Carisma Therapeutics
Carisma's innovative approach has the potential to create life-changing therapies for patients with fibrosis, oncology and autoimmune disorders.
CARsgen Therapeutics
CARsgen Therapeutics is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. As one of the leading companies in the field of CAR T-cell therapies, CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production.
Cartography Biosci
Cartography is shaping a world in which cancer immunotherapies are designed around and directed toward the safest and most effective targets.
Casablanca Cancer Center
In French: "Le Casablanca Cancer Center (CCC) de l’Hôpital Cheikh Khalifa, est un centre d’excellence aux normes internationales, offrant une prise en charge de tous les types de cancers, y compris les cancers hématologiques, les cancers de l’enfant, de l’adolescent et de l’adulte durant toutes les phases de la maladie."
Catena Bio
CatenaBio was founded to enable the next generation of novel therapeutics by forming never-before-possible structures using our proprietary technology, which can combine therapeutics with complete freedom. We have developed the CysTyr� platform utilizing the novel Catenase� enzyme, engineered to couple tyrosine residues with cysteine residues to form our proprietary C-Y Bond�. Our platform redefines what therapeutics are possible and has successfully combined a diverse array of compounds, including toxins, isotope chelators, nucleic acids, peptides, enzymes, cytokines, nanobodies, viral capsids, and even whole cells.
CCF (Congo Cancer Foundation)
Congo Cancer Organization (CCF) in a non-profit organization whose mission is the improve cancer control in the Democratic Republic of the Congo. It is involved in many activities including in the field of education, research and patient-centered health care delivery. Since its inception, CCF has been instrumental in various activities: implementation and conduct of free screening services mainly targeting disadvantaged areas of the Kinshasa region, awareness activities about cervical and breast cancer within communities and engaging local spiritual and community leaders as they culturally influence how the population perceive cancer.
CCI (Childhood Cancer International)
CCI is the largest patient support organization for childhood cancer. It is a global, parent-driven non-profit that represents more than 221 member organisations in 102 countries and 6 continents, childhood cancer survivor associations, childhood cancer support groups, and cancer societies, in over 90 countries, across 6 continents
CCI Europe (Childhood Cancer International Europe)
CCI Europe is the European branch of Childhood Cancer International (CCI). The Board of CCI is interlinked with the CCI Europe Regional Committee fostering a strong partnership and exchange of knowledge across the different geographical scopes. CCI Europe is the biggest pan-European childhood cancer parents’ and survivors’ organisation. It represents childhood cancer parents´ and survivors´ groups and other childhood cancer organisations.